The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Drug Treatment Effects on Disease Progression
Abstract
Degenerative diseases are characterized by a worsening of disease status over time. The rate of deterioration is determined by the natural rate of progression of the disease and by the effect of drug treatments. A goal of drug treatment is to slow disease progression. Drug treatments can be categorized as symptomatic or protective. Symptomatic treatments do not affect the rate of disease progression whereas protective treatments have the ability to slow disease progression down. Many current methods for describing disease progression have two common drawbacks: a linear relationship between time and disease status is assumed, and within- and between-subject variability is ignored. Disease progress models combined with pharmacokinetic pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833
Tesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y., O'Brien, P. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1998) · Neurology · doi:10.1212/wnl.51.4.993 · Cited by 666
Kaye, J. A., Swihart, T., Howieson, D., Dame, A., Moore, M. M., Karnos, T., Camicioli, R., Ball, M., Oken, B., & Sexton, G. (1997) · Neurology · doi:10.1212/wnl.48.5.1297 · Cited by 399
A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease
Weyer, G., Babej-Dölle, R. M., Hadler, D., Hofmann, S., & Herrmann, W. M. (2008) · Neuropsychobiology · doi:10.1159/000119366 · Cited by 120
Cited by
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
Accurate telemonitoring of Parkinson’s disease progression by non-invasive speech tests
Tsanas, A., Little, M., McSharry, P., & Ramig, L. (2009) · Nature Precedings · doi:10.1038/npre.2009.3920.1 · Cited by 829
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
DANHOF, M., DELANGE, E., DELLAPASQUA, O., PLOEGER, B., & VOSKUYL, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.007 · Cited by 287
Treatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C., Koller, W., Poewe, W., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Helmlinger, G., Al-Huniti, N., Aksenov, S., Peskov, K., Hallow, K. M., Chu, L., Boulton, D., Eriksson, U., Hamrén, B., Lambert, C., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.028 · Cited by 33
Metadata
- Authors
- Chan, P., & Holford, N.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2001-04
- Volume
- 41
- Issue
- 1
- Pages
- 625-659
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2115682190
- Cited by
- 160
- References
- 8
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Treatment Effects on Disease Progression. https://app.cochat.ai/papers/10.1146/annurev.pharmtox.41.1.625
- The paper
- Chan, P., & Holford, N. (2001). Drug Treatment Effects on Disease Progression. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pharmtox.41.1.625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.